Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Formally Adopts GS1 Codes for Electronic Package Inserts; Rule to Take Effect August 1
The Ministry of Health, Labor and Welfare (MHLW) on February 19 issued a notification informing that it has officially decided that GS1 codes will be used to access package insert information in electronic form under the amended Pharmaceuticals and Medical…
To read the full story
Related Article
- Downloads of FPMAJ’s E-Labeling App on Track to Target 50,000 as Legal Enforcement Approaches
July 14, 2021
- Industry Group Poised for Pilot Rollout of E-Labeling App in April, Looks to Sales Reps for Popularization
March 26, 2021
- MHLW Unveils Draft Ordinance for Electronic Distribution of Package Inserts; Use of GS1 Codes Expected
November 10, 2020
REGULATORY
- Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
- Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026
- Govt Panel Urges 2027 Bill to Expand Secondary Use of Health Data
June 30, 2026
- Japan Panel OKs Carvykti’s Earlier Use in Multiple Myeloma
June 30, 2026
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…